Pearl River Capital, LLC Exelixis, Inc. Transaction History

Pearl River Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $110,075 - $127,955	-7,358 Reduced 25.11%	21,942 $351,000
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $138,987 - $197,401	-8,864 Reduced 23.23%	29,300 $459,000
Q2 2022 Aug 12, 2022	BUY	$17.44 - $23.16 $665,580 - $883,878	38,164 New	38,164 $795,000
Q3 2021 Nov 12, 2021	SELL	$16.3 - $21.14 $637,770 - $827,144	-39,127 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $702,329 - $1 Million	39,127 New	39,127 $713,000

501

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.5B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.